The contraceptive pills market is poised to register a CAGR of 9.0% during the forecast period (2024-2029).

The COVID-19 pandemic had a substantial impact on the contraceptive pills market. Several guidelines are being introduced pertaining to the contraceptive pills that have benefitted the market amid the COVID-19 pandemic. For instance, as per the “Guidelines for provision of Family Planning services during and post COVID-19 Pandemic” published in October 2023, by the Government of India, oral contraceptive pills should be freely available in all public health facilities (including the COVID care facilities). As per the same source, extra packets (at least 2 months supply) of oral contraceptive pills can be handed over to repeat clients to avoid multiple contacts. Thus, the demand for contraceptive pills remained significant during the pandemic. However, with the introduction of vaccines, government authorities and healthcare organizations have recommended reducing the consumption of contraceptive pills before the administration of vaccines. For instance, as per an April 2023 update by the Taiwan Centers for Disease Control, the Advisory Committee on Immunization Practices (ACIP), the ACIP made a resolution to add related reminding messages on the notice of "precautions to take before COVID-19 vaccination with AstraZeneca vaccine", taking contraceptive pills and undergoing hormone therapy are risk factors for blood clotting, people receiving these two treatments are advised to pause the treatments at least 28 days prior to and after inoculation at this stage.

Further, the increasing rate of unintended pregnancies is a major factor driving the demand for contraceptive pills, thereby contributing to the market growth. For instance, as per a March 2023 update by the United Nations Populations Fund, the number of unintended pregnancies was 1.4 million during 2022 across 115 low- and middle-income countries. Thus, such statistics indicate the increasing demand for contraceptive pills across the globe, thereby contributing to the market growth.

However, side effects associated with the use of contraceptive drugs and increased usage of alternative birth control methods are the factors hindering the market growth over the forecast period.

Key Market Trends

The Generic Segment is Expected to Hold the Largest Share of the Market

By category, the generic segment is expected to witness significant growth. The generic segment has the largest share in the market due to the widespread adoption of generic contraceptives, owing to their low prices and market availability. For instance, in February 2024, Asda lowered the price of its generic emergency hormonal contraception (EHC) pill to GBP 9.89 to ensure it is more accessible for women in the United Kingdom.

Furthermore, the increasing need for population control and the rising incidence of abortion has driven the growth of generic contraceptive pills in the market. Thus, several market players are engaged in the implementation of strategic initiatives, thereby boosting the market growth. For instance, in March 2023, Mayne Pharma Group Limited commercially launched a generic version of ORTHO-CEPT (desogestrel and Ethinyl estradiol 0.15 mg / 0.03 mg) tablets to customers in the United States. Such developments are likely to have a positive impact on the adoption of generic contraceptive pills among women.

Hence, due to the above-mentioned factors, the segment is expected to witness significant growth during the forecast period.

North America is Expected to Holds the Largest Share in the Market

Within North America, the United States holds a major share of the market owing to rapid developments in the healthcare infrastructure and high awareness about contraceptive pills in the region. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC), in 2022, 14 percent of women aged 15-49 currently use contraceptive pills. Thus, the consumption of contraceptive pills in the United States is significant and is expected to continue over the coming years.

Several organizations are also engaged in the implementation of strategic initiatives in the country. For instance, as per the Bill & Melinda Gates Foundation data published in 2024, the foundation is aiming to offer USD 280 million per year from 2023 to 2032 for developing new and improved contraceptive technologies, support family planning programs that reflect the preferences of local communities, and enable women and girls to be in control of their contraceptive care. Such developments are anticipated to boost the adoption of oral contraceptive pills in the country, thereby boosting the market growth.

Hence, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.

Competitive Landscape

The competition in the market is set to intensify as several key players are focusing on the expansion of their product portfolios through acquisitions and collaborations. The contraceptive pills market is expected to open up several opportunities for the new players, as well as the currently established market leaders. The key players in the market include Bayer Healthcare, Amgen Inc., Pfizer, and Teva, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Increasing Rate of Unintended Pregnancies

    • 4.2.2 Growing Awareness About Contraceptive Pills

    • 4.2.3 Ease of Use and Low Cost

  • 4.3 Market Restraints

    • 4.3.1 Side Effects Associated with the Use of Contraceptive Drugs

    • 4.3.2 Increased Usage of Alternative Birth Control Methods

  • 4.4 Porter's Five Forces Analysis

    • 4.4.1 Threat of New Entrants

    • 4.4.2 Bargaining Power of Buyers/Consumers

    • 4.4.3 Bargaining Power of Suppliers

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value- USD million)

  • 5.1 By Hormone Type

    • 5.1.1 Progestin Pills

    • 5.1.2 Combination Pills

      • 5.1.2.1 Monophasic
      • 5.1.2.2 Triphasic
      • 5.1.2.3 Other Combination Pills

  • 5.2 By Category

    • 5.2.1 Generic

    • 5.2.2 Branded

  • 5.3 By Geography

    • 5.3.1 North America

      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico

    • 5.3.2 Europe

      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe

    • 5.3.3 Asia-Pacific

      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific

    • 5.3.4 Middle-East and Africa

      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa

    • 5.3.5 South America

      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 Bayer Healthcare

    • 6.1.2 Amneal Pharmaceuticals LLC

    • 6.1.3 Teva Pharmaceuticals

    • 6.1.4 Abbvie Inc. (Allergan PLC)

    • 6.1.5 Pfizer Inc

    • 6.1.6 Johnson & Johnson

    • 6.1.7 Aurobindo Pharma Limited

    • 6.1.8 Organon International (Merck & Co. Inc.)

    • 6.1.9 Sanofi SA

    • 6.1.10 Mayne Pharma

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS